Marco Davila, Senior Vice President, Translational Research at Roswell Park Comprehensive Cancer Center, shared on LinkedIn:
“After a little help from the Microsoft Outlook outage in building suspense, I’m pleased to share my candidacy for Director from Laboratory Science on the ASTCT Board of Directors.
For two decades, my work across Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, and Roswell Park Comprehensive Cancer Center has connected laboratory discovery with clinical care in cell and gene therapy. That work has depended on collaboration, scientific exchange, and the contributions of many colleagues in our ASTCT community.
If elected, I would bring experience in scientific review, clinical translation, and program building to Board decisions about research priorities, partnerships, and resources. My central priority would be strengthening research and education at Tandem and throughout the year, including basic and translational science, scientific exchange, and mentorship.
To my fellow ASTCT members eligible to vote: I would appreciate your support and your vote.
You can review the candidates and access the ballot by signing in with your ASTCT account.”
The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional association representing more than 3,900 physicians, researchers and healthcare professionals across more than 50 countries. Dedicated to advancing hematopoietic cell transplantation and cellular and gene therapies, ASTCT supports groundbreaking research, professional education, clinical excellence and advocacy to improve patient outcomes.
Its Board of Directors provides leadership and strategic oversight, with dedicated representation for laboratory science, community and clinical practice, and other areas of the field.
Other articles featuring Marco Davila on OncoDaily.